{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:44:07Z","timestamp":1792467847541,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8187111481"],"award-info":[{"award-number":["8187111481"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002409"],"award-info":[{"award-number":["82002409"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073396"],"award-info":[{"award-number":["82073396"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2020A1515010020"],"award-info":[{"award-number":["2020A1515010020"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00280-022-04456-w","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T16:03:09Z","timestamp":1659542589000},"page":"229-237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies"],"prefix":"10.1007","volume":"90","author":[{"given":"Jinhui","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore J.","family":"Salamone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaodong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1173-8441","authenticated-orcid":false,"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"issue":"20","key":"4456_CR1","doi-asserted-by":"publisher","first-page":"10435","DOI":"10.1016\/S0021-9258(19)68639-4","volume":"256","author":"N Kumar","year":"1981","unstructured":"Kumar N (1981) Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256(20):10435\u201310441","journal-title":"J Biol Chem"},{"issue":"18","key":"4456_CR2","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.E14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver BA (2014) How Taxol\/paclitaxel kills cancer cells. Mol Biol Cell 25(18):2677\u20132681. https:\/\/doi.org\/10.1091\/mbc.E14-04-0916","journal-title":"Mol Biol Cell"},{"issue":"26","key":"4456_CR3","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666\u20132676. https:\/\/doi.org\/10.1056\/NEJMoa072113","journal-title":"N Engl J Med"},{"issue":"25","key":"4456_CR4","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.1200\/jco.2005.55.405","volume":"23","author":"CP Belani","year":"2005","unstructured":"Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23(25):5883\u20135891. https:\/\/doi.org\/10.1200\/jco.2005.55.405","journal-title":"J Clin Oncol"},{"issue":"10","key":"4456_CR5","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/annonc\/mdl151","volume":"17","author":"G Fountzilas","year":"2006","unstructured":"Fountzilas G, Papakostas P, Dafni U, Makatsoris T, Karina M, Kalogera-Fountzila A, Maniadakis N, Aravantinos G, Syrigos K, Bamias A, Christodoulou C, Economopoulos T, Kalofonos H, Nikolaou A, Angouridakis N, Stathopoulos G, Bafaloukos D, Pavlidis N, Daniilidis J (2006) Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 17(10):1560\u20131567. https:\/\/doi.org\/10.1093\/annonc\/mdl151","journal-title":"Ann Oncol"},{"issue":"17","key":"4456_CR6","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/jco.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194\u20133200. https:\/\/doi.org\/10.1200\/jco.2003.02.153","journal-title":"J Clin Oncol"},{"issue":"5","key":"4456_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1517\/14740338.6.5.609","volume":"6","author":"NI Marupudi","year":"2007","unstructured":"Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H (2007) Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6(5):609\u2013621. https:\/\/doi.org\/10.1517\/14740338.6.5.609","journal-title":"Expert Opin Drug Saf"},{"issue":"20","key":"4456_CR8","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1200\/jco.2001.19.20.4065","volume":"19","author":"A Henningsson","year":"2001","unstructured":"Henningsson A, Karlsson MO, Vigan\u00f2 L, Gianni L, Verweij J, Sparreboom A (2001) Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 19(20):4065\u20134073. https:\/\/doi.org\/10.1200\/jco.2001.19.20.4065","journal-title":"J Clin Oncol"},{"issue":"24","key":"4456_CR9","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542\u20132550. https:\/\/doi.org\/10.1056\/NEJMoa061884","journal-title":"N Engl J Med"},{"issue":"1","key":"4456_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/jco.2007.13.1144","volume":"26","author":"SS Ramalingam","year":"2008","unstructured":"Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH (2008) Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 26(1):60\u201365. https:\/\/doi.org\/10.1200\/jco.2007.13.1144","journal-title":"J Clin Oncol"},{"issue":"9","key":"4456_CR11","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1002\/cam4.2955","volume":"9","author":"T Aagaard","year":"2020","unstructured":"Aagaard T, Reekie J, J\u00f8rgensen M, Roen A, Daugaard G, Specht L, Sengel\u00f8v H, Mocroft A, Lundgren J, Helleberg M (2020) Mortality and admission to intensive care units after febrile neutropenia in patients with cancer. Cancer Med 9(9):3033\u20133042. https:\/\/doi.org\/10.1002\/cam4.2955","journal-title":"Cancer Med"},{"issue":"10","key":"4456_CR12","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258\u20132266. https:\/\/doi.org\/10.1002\/cncr.21847","journal-title":"Cancer"},{"issue":"10","key":"4456_CR13","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40262-016-0395-2","volume":"55","author":"Y Ma","year":"2016","unstructured":"Ma Y, Lin Y, Zou B, Liu W, Zhang Y, Zhao L, Huang Y, Yang Y, Fang W, Zhao Y, Sheng J, Qin T, Hu Z, Salamone SJ, Li Y, Zhang L, Zhao H (2016) Pharmacokinetic and pharmacodynamic analyses of 5-fluorouracil in east-asian patients with nasopharyngeal carcinoma. Clin Pharmacokinet 55(10):1205\u20131216. https:\/\/doi.org\/10.1007\/s40262-016-0395-2","journal-title":"Clin Pharmacokinet"},{"key":"4456_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04387-y","author":"Z Tong","year":"2022","unstructured":"Tong Z, Cheng M, Yu Y, Yu J, Yin Y, Liu J, Zhang S, Jiang S, Dong M (2022) Correlation between pharmacokinetic parameters of 5-fluorouracil and related metabolites and adverse reactions in East-Asian patients with advanced colorectal cancer. Cancer Chemother Pharmacol. https:\/\/doi.org\/10.1007\/s00280-021-04387-y","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4456_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1200\/jco.1997.15.1.317","volume":"15","author":"MT Huizing","year":"1997","unstructured":"Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB, Postmus PE, van Zandwijk N, Koolen MG, ten Bokkel Huinink WW, van der Vijgh WJ, Bierhorst FJ, Lai A, Dalesio O, Pinedo HM, Veenhof CH, Beijnen JH (1997) Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol 15(1):317\u2013329. https:\/\/doi.org\/10.1200\/jco.1997.15.1.317","journal-title":"J Clin Oncol"},{"issue":"1","key":"4456_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/jco.1995.13.1.180","volume":"13","author":"L Gianni","year":"1995","unstructured":"Gianni L, Kearns CM, Giani A, Capri G, Vigan\u00f3 L, Lacatelli A, Bonadonna G, Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic\/pharmacodynamic relationships in humans. J Clin Oncol 13(1):180\u2013190. https:\/\/doi.org\/10.1200\/jco.1995.13.1.180","journal-title":"J Clin Oncol"},{"issue":"11","key":"4456_CR17","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1097\/JTO.0b013e31822722b6","volume":"6","author":"Y Hasegawa","year":"2011","unstructured":"Hasegawa Y, Kawaguchi T, Kubo A, Ando M, Shiraishi J, Isa S, Tsuji T, Tsujino K, Ou SH, Nakagawa K, Takada M (2011) Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials. J Thorac Oncol 6(11):1881\u20131888. https:\/\/doi.org\/10.1097\/JTO.0b013e31822722b6","journal-title":"J Thorac Oncol"},{"issue":"9","key":"4456_CR18","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/bf03261934","volume":"51","author":"M Joerger","year":"2012","unstructured":"Joerger M, Kraff S, Huitema AD, Feiss G, Moritz B, Schellens JH, Beijnen JH, Jaehde U (2012) Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet 51(9):607\u2013617. https:\/\/doi.org\/10.1007\/bf03261934","journal-title":"Clin Pharmacokinet"},{"issue":"24","key":"4456_CR19","doi-asserted-by":"publisher","first-page":"8325","DOI":"10.1158\/1078-0432.Ccr-04-1078","volume":"10","author":"AA Miller","year":"2004","unstructured":"Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Ratain MJ (2004) Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res 10(24):8325\u20138331. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-1078","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4456_CR20","first-page":"599","volume":"1","author":"T Ohtsu","year":"1995","unstructured":"Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N (1995) Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1(6):599\u2013606","journal-title":"Clin Cancer Res"},{"issue":"21","key":"4456_CR21","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1158\/1078-0432.Ccr-07-0064","volume":"13","author":"M Joerger","year":"2007","unstructured":"Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, F\u00e9ty R, Van der Vijgh WJ, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH (2007) Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 13(21):6410\u20136418. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-0064","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4456_CR22","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdw290","volume":"27","author":"M Joerger","year":"2016","unstructured":"Joerger M, von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler TC, Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp HG, Behringer DM, Ko YD, Hilger RA, Roessler M, Kloft C, Henrich A, Moritz B, Miller MC, Salamone SJ, Jaehde U (2016) Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 27(10):1895\u20131902. https:\/\/doi.org\/10.1093\/annonc\/mdw290","journal-title":"Ann Oncol"},{"issue":"6","key":"4456_CR23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1097\/FTD.0b013e318296be01","volume":"35","author":"DJ Cline","year":"2013","unstructured":"Cline DJ, Zhang H, Lundell GD, Harney RL, Riaz HK, Jarrah J, Li Y, Miyazaki M, Courtney JB, Baburina I, Salamone SJ (2013) Development and evaluation of a nanoparticle-based immunoassay for determining paclitaxel concentrations on routine clinical analyzers. Ther Drug Monit 35(6):809\u2013815. https:\/\/doi.org\/10.1097\/FTD.0b013e318296be01","journal-title":"Ther Drug Monit"},{"issue":"6","key":"4456_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/ftd.0000000000000446","volume":"39","author":"M Joerger","year":"2017","unstructured":"Joerger M, Kraff S, Jaehde U, Hilger RA, Courtney JB, Cline DJ, Jog S, Baburina I, Miller MC, Salamone SJ (2017) Validation of a commercial assay and decision support tool for routine paclitaxel therapeutic drug monitoring (TDM). Ther Drug Monit 39(6):617\u2013624. https:\/\/doi.org\/10.1097\/ftd.0000000000000446","journal-title":"Ther Drug Monit"},{"issue":"6","key":"4456_CR25","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.surg.2015.12.029","volume":"159","author":"JV Carter","year":"2016","unstructured":"Carter JV, Pan J, Rai SN, Galandiuk S (2016) ROC-ing along: evaluation and interpretation of receiver operating characteristic curves. Surgery 159(6):1638\u20131645. https:\/\/doi.org\/10.1016\/j.surg.2015.12.029","journal-title":"Surgery"},{"issue":"21","key":"4456_CR26","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1200\/jco.2008.20.8793","volume":"27","author":"DR Gandara","year":"2009","unstructured":"Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN Jr, Coltman CA Jr, Fukuoka M, Saijo N, Fukushima M, Mack PC (2009) Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 27(21):3540\u20133546. https:\/\/doi.org\/10.1200\/jco.2008.20.8793","journal-title":"J Clin Oncol"},{"issue":"5","key":"4456_CR27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00228-021-03129-6","volume":"77","author":"C Zhao","year":"2021","unstructured":"Zhao C, Wang F, Huang J, Lv Y, Yin F, Liu H, Zheng Q, Li L (2021) The impacts of race and regimens on the efficacy and safety of paclitaxel and platinum combination treatment for patients with advanced non-small cell lung cancer. Eur J Clin Pharmacol 77(5):685\u2013695. https:\/\/doi.org\/10.1007\/s00228-021-03129-6","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"4456_CR28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2165\/00003088-199427040-00002","volume":"27","author":"DS Sonnichsen","year":"1994","unstructured":"Sonnichsen DS, Relling MV (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27(4):256\u2013269. https:\/\/doi.org\/10.2165\/00003088-199427040-00002","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"4456_CR29","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1349-7006.1994.tb02906.x","volume":"85","author":"T Tamura","year":"1994","unstructured":"Tamura T, Sasaki Y, Eguchi K, Shinkai T, Ohe Y, Nishio M, Kunikane H, Arioka H, Karato A, Omatsu H et al (1994) Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion. Jpn J Cancer Res Gann 85(10):1057\u20131062. https:\/\/doi.org\/10.1111\/j.1349-7006.1994.tb02906.x","journal-title":"Jpn J Cancer Res Gann"},{"issue":"2","key":"4456_CR30","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/jco.1999.17.2.676","volume":"17","author":"CP Belani","year":"1999","unstructured":"Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J, Egorin MJ (1999) Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 17(2):676\u2013684. https:\/\/doi.org\/10.1200\/jco.1999.17.2.676","journal-title":"J Clin Oncol"},{"issue":"4","key":"4456_CR31","first-page":"767","volume":"5","author":"EK Rowinsky","year":"1999","unstructured":"Rowinsky EK, Jiroutek M, Bonomi P, Johnson D, Baker SD (1999) Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res 5(4):767\u2013774","journal-title":"Clin Cancer Res"},{"issue":"14","key":"4456_CR32","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/s0959-8049(02)00231-9","volume":"38","author":"T Kasai","year":"2002","unstructured":"Kasai T, Oka M, Soda H, Tsurutani J, Fukuda M, Nakamura Y, Kawabata S, Nakatomi K, Nagashima S, Takatani H, Fukuda M, Kinoshita A, Kohno S (2002) Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer. Eur J Cancer (Oxford, England: 1990) 38(14):1871\u20131878. https:\/\/doi.org\/10.1016\/s0959-8049(02)00231-9","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"5","key":"4456_CR33","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1365-2125.2007.02956.x","volume":"64","author":"M Joerger","year":"2007","unstructured":"Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H, Schellens JH, Beijnen JH, Vermorken JB (2007) Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol 64(5):622\u2013633. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02956.x","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"4456_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/jjco\/hyp059","volume":"39","author":"K Naoki","year":"2009","unstructured":"Naoki K, Kunikane H, Fujii T, Tsujimura S, Hida N, Okamoto H, Watanabe K (2009) Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI. Jpn J Clin Oncol 39(9):569\u2013575. https:\/\/doi.org\/10.1093\/jjco\/hyp059","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"4456_CR35","first-page":"261","volume":"33","author":"Y Tsubata","year":"2013","unstructured":"Tsubata Y, Okimoto T, Miura K, Karino F, Iwamoto S, Tada M, Honda T, Hamaguchi S, Ohe M, Sutani A, Kuraki T, Hamada A, Isobe T (2013) Phase I clinical and pharmacokinetic study of bi-weekly carboplatin\/paclitaxel chemotherapy in elderly patients with advanced non-small cell lung cancer. Anticancer Res 33(1):261\u2013266","journal-title":"Anticancer Res"},{"issue":"2","key":"4456_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193500","volume":"13","author":"B Posocco","year":"2018","unstructured":"Posocco B, Buzzo M, Follegot A, Giodini L, Sorio R, Marangon E, Toffoli G (2018) A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of paclitaxel and 6\u03b1-hydroxy-paclitaxel in human plasma: Development, validation and application in a clinical pharmacokinetic study. PLoS ONE 13(2):e0193500. https:\/\/doi.org\/10.1371\/journal.pone.0193500","journal-title":"PLoS ONE"},{"issue":"5","key":"4456_CR37","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00280-015-2724-9","volume":"75","author":"S Kraff","year":"2015","unstructured":"Kraff S, Nieuweboer AJ, Mathijssen RH, Baty F, de Graan AJ, van Schaik RH, Jaehde U, Joerger M (2015) Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. Cancer Chemother Pharmacol 75(5):975\u2013983. https:\/\/doi.org\/10.1007\/s00280-015-2724-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"4456_CR38","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1158\/1078-0432.Ccr-18-0656","volume":"24","author":"DL Hertz","year":"2018","unstructured":"Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Lavoie Smith EM, Henry NL (2018) Paclitaxel plasma concentration after the first infusion predicts treatment-limiting peripheral neuropathy. Clin Cancer Res 24(15):3602\u20133610. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0656","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4456_CR39","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ijrobp.2007.10.011","volume":"71","author":"Y Chen","year":"2008","unstructured":"Chen Y, Pandya KJ, Feins R, Johnstone DW, Watson T, Smudzin T, Keng PC (2008) Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 71(2):407\u2013413. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.10.011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4456_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2174\/1574892813666180305170439","volume":"13","author":"DS Xin","year":"2018","unstructured":"Xin DS, Zhou L, Li CZ, Zhang SQ, Huang HQ, Qiu GD, Lin LF, She YQ, Zheng JT, Chen C, Fang L, Chen ZS, Zhang SY (2018) TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients. Recent Patents Anti-Cancer Drug Discov 13(3):341\u2013347. https:\/\/doi.org\/10.2174\/1574892813666180305170439","journal-title":"Recent Patents Anti-Cancer Drug Discov"},{"issue":"10","key":"4456_CR41","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1111\/bcp.13982","volume":"85","author":"J Zhang","year":"2019","unstructured":"Zhang J, Zhou F, Qi H, Ni H, Hu Q, Zhou C, Li Y, Baburina I, Courtney J, Salamone SJ (2019) Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. Br J Clin Pharmacol 85(10):2292\u20132301. https:\/\/doi.org\/10.1111\/bcp.13982","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"4456_CR42","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1023\/a:1008279503428","volume":"8","author":"G Fountzilas","year":"1997","unstructured":"Fountzilas G, Skarlos D, Athanassiades A, Kalogera-Fountzila A, Samantas E, Bacoyiannis C, Nicolaou A, Dombros N, Briasoulis E, Dinopoulou M, Stathopoulos G, Pavlidis N, Kosmidis P, Daniilidis J (1997) Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 8(5):451\u2013455. https:\/\/doi.org\/10.1023\/a:1008279503428","journal-title":"Ann Oncol"},{"issue":"2","key":"4456_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1023\/a:1008390929826","volume":"10","author":"EH Tan","year":"1999","unstructured":"Tan EH, Khoo KS, Wee J, Fong KW, Lee KS, Lee KM, Chua ET, Tan T, Khoo-Tan HS, Yang TL, Au E, Tao M, Ong YK, Chua EJ (1999) Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 10(2):235\u2013237. https:\/\/doi.org\/10.1023\/a:1008390929826","journal-title":"Ann Oncol"},{"issue":"5","key":"4456_CR44","doi-asserted-by":"publisher","first-page":"236","DOI":"10.21037\/atm.2020.01.76","volume":"8","author":"Y Ma","year":"2020","unstructured":"Ma Y, Lin Q, Yang Y, Liang W, Salamone SJ, Li Y, Lin Y, Zhao H, Zhao Y, Fang W, Huang Y, Zhang L (2020) Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients. Ann Transl Med 8(5):236. https:\/\/doi.org\/10.21037\/atm.2020.01.76","journal-title":"Ann Transl Med"},{"issue":"3","key":"4456_CR45","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1124\/jpet.120.000053","volume":"375","author":"FW Ojara","year":"2020","unstructured":"Ojara FW, Henrich A, Frances N, Huisinga W, Hartung N, Joerger M, Kloft C (2020) Time-to-event analysis of paclitaxel-associated peripheral neuropathy in advanced non-small-cell lung cancer highlighting key influential treatment\/patient factors. J Pharmacol Exp Ther 375(3):430\u2013438. https:\/\/doi.org\/10.1124\/jpet.120.000053","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04456-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04456-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04456-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T15:03:29Z","timestamp":1661353409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04456-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["4456"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04456-w","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"assertion":[{"value":"13 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Li Zhang reports receiving research support from Bristol-Myers Squibb. Other authors declare no conflict of interest in connection with the work submitted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}